Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a crossover study of ACD440 gel in peripheral neuropathic pain with sensory hypersensitivity
2022-000902-82Phase 2Completed
- Sponsor
- AlzeCure Pharma
- Start
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of acd440 in Peripheral neuropathic pain (2 arms), sponsored by AlzeCure Pharma. Primary endpoint: Change in evoked pain. Started Mar 2022; status: completed.
02
Drugs
acd440
03
Conditions
Peripheral neuropathic pain
Beyond the preview
Go deeper on 2022-000902-82.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-000902-82.